Femasys
FEMY

$1.18

0.85%

Market Cap: $26.2M

About: Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.

Employees: 34

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

18% more funds holding

Funds holding: 22 [Q1] → 26 (+4) [Q2]

0.28% more ownership

Funds ownership: 6.82% [Q1] → 7.1% (+0.28%) [Q2]

21% less capital invested

Capital invested by funds: $2.29M [Q1] → $1.8M (-$490K) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$10

747%

upside

Avg. target

$11.75

896%

upside

High target

$13

1,002%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Emily Bodnar 32% 1-year accuracy 29 / 92 met price target	917%upside $12	Buy Reiterated	12 Sept 2024
Chardan Capital Keay Nakae 38% 1-year accuracy 20 / 52 met price target	747%upside $10	Buy Maintained	14 Aug 2024
HC Wainwright & Co. Emily Bodnar 32% 1-year accuracy 29 / 92 met price target	917%upside $12	Buy Maintained	9 Aug 2024
HC Wainwright & Co. Emily Bodnar 32% 1-year accuracy 29 / 92 met price target	1,002%upside $13	Buy Reiterated	20 Jun 2024

See Analyst Rankings

Financial journalist opinion

Based on 9 articles about FEMY published over the past 30 days

Femasys Announces Infertility Clinic Customers from Coast to Coast

Leading medical clinics become key regional resources to offer FemaSeed infertility treatment Leading medical clinics become key regional resources to offer FemaSeed infertility treatment

Femasys Announces Infertility Clinic Customers from Coast to Coast

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products

Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market

Zacks Investment Research

Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device

FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.

Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the Canadian Fertility and Andrology Society's (CFAS) 70th Annual Meeting, to be held September 12-14, 2024 at The Westin Bayshore, Vancouver, British Columbia. The Company will be exhibiting at Booth #S26.

Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting

Zacks Investment Research

Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI

FEMY's eco-friendly FemVue MINI receives CE Mark and Health Canada approval, advancing sustainable fallopian tube assessment technology in Europe and Canada.

Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference. The fireside chat will be hosted by Emily Bodnar, Life Sciences Analyst. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel.

Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces that it has received CE mark certification and product approval from Health Canada, the Public Health Agency of Canada, for its compact, eco-friendly FemVue® MINI for fallopian tube assessment.

Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

The Congresswoman representing Georgia's 7th district in the U.S. House of Representatives toured Femasys' facilities to gain a better understanding of our advancements for women's reproductive health The Congresswoman representing Georgia's 7th district in the U.S. House of Representatives toured Femasys' facilities to gain a better understanding of our advancements for women's reproductive health

Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters

Zacks Investment Research

Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates

Femasys Inc. (FEMY) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.22 per share a year ago.

Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates

See News Rankings